Anticancer agent 232

• Description:

  Anticancer agent 232 (compound 12f) is a glycohybrid designed using 1-azidoglycosides derived from d-glucose, d-galactose, and d-mannose. The IC50 values ​​of anticancer agent 232 against MCF-7 and MDA-MB231 cells are 1.05 μM and 18.03 μM, respectively[1].

• UNSPSC:

  12352005

• Target:

  Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/anticancer-agent-232.html

• Smiles:

  O=C (C1=CC=CO1) /C=C/C2=CN (CC3=CN ([C@H]4O[C@H] (COC (C) =O) [C@H] (OC (C) =O) [C@H] (OC (C) =O) [C@H]4OC (C) =O) N=N3) C5=CC=C (Br) C=C52

• Molecular Formula:

  C32H31BrN4O11

• Molecular Weight:

  727.51

• References & Citations:

  [1]Tyagi R, et al. Efficient synthesis of indole-chalcones based glycohybrids and their anticancer activity. Bioorg Med Chem. 2024 Jul 15;109:117778.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  9007-83-4